DRG Epidemiology’s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of muscular dystrophy for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology’s muscular dystrophy forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of muscular dystrophy over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following muscular dystrophy patient populations:

  • Diagnosed incidence of Duchenne muscular dystrophy (DMD).
  • Diagnosed prevalence of Becker muscular dystrophy.
  • Diagnosed prevalence of congenital muscular dystrophy.
  • Diagnosed prevalence of distal muscular dystrophy.
  • Diagnosed prevalence of DMD.
  • Diagnosed prevalence of Emery-Dreifuss muscular dystrophy.
  • Diagnosed prevalence offacioscapulohumeral muscular dystrophy.
  • Diagnosed prevalence of limb-girdle muscular dystrophy.
  • Diagnosed prevalence of myotonic dystrophy.
  • Diagnosed prevalence ofoculopharyngeal muscular dystrophy.
  • Diagnosed prevalenceofDMD by ambulation.
  • Diagnosed prevalence of DMDamenable to exon-skipping therapy.
  • Diagnosed prevalenceofDMD by nonsense mutations.

Note: Coverage may vary by country and region.

Table of contents

  • Muscular Dystrophy - Epidemiology - Mature Markets

Author(s): Shilpa Thakur; Abey John, MPH

Shilpa Thakur is a medical graduate with a M.P.H from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics. She specializes in developing epidemiological forecasts for the multiple indications within the DRG syndicated portfolio.

Prior to joining Decision Resources, she monitored HIV sentinel surveillance 2016-2017 in Himachal Pradesh. She also has worked on to see the patterns of Antimicrobial resistance in India.


Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

Related Reports

Muscular Dystrophy - Landscape & Forecast - Disease Landscape & Forecast

Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. There is a high unmet need for...

View Details